The chart below shows how AORT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AORT sees a +0.14% change in stock price 10 days leading up to the earnings, and a +3.84% change 10 days following the report. On the earnings day itself, the stock moves by +0.01%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Constant Currency Revenue Growth: Total constant currency revenue growth of 10% excluding PerClot, indicating strong overall performance.
EBITDA Margin Expansion: Expanded EBITDA margins by 310 basis points, resulting in adjusted EBITDA growth of 32% year-over-year, showcasing operational efficiency.
Revenue Increase and Market Gains: On-X revenue increased 10% year-over-year on a constant-currency basis, reflecting market share gains and strong clinical benefits.
Stent Graft Revenue Growth: Stent graft revenues grew 8% on a constant currency basis, indicating continued demand and growth in this product category.
BioGlue Growth Prospects: BioGlue grew 7% on a constant currency basis, with regulatory approval in China expected to drive future growth.
Regional Revenue Growth: Latin America and Asia-Pacific regions delivered constant-currency revenue growth of 26% and 11% respectively, highlighting successful expansion efforts.
Humanitarian Device Exemption Impact: The Humanitarian Device Exemption (HDE) for AMDS represents a significant milestone, allowing for commercial distribution prior to PMA approval, which is expected to enhance revenue.
Clinical Benefits of AMDS Trial: Data from the AMDS PERSEVERE trial demonstrated significant clinical benefits, including a 72% reduction in mortality, reinforcing the product's potential impact.
Future Performance Expectations: Expectations for 2025 include constant currency growth of 10% to 14%, with adjusted EBITDA projected to grow 18% to 28% over 2024, indicating strong future performance.
Negative
Earnings Miss Reported: Artivion, Inc. reported a significant earnings miss with an EPS of $-0.39, falling short of expectations of $0.12.
Cyber Incident Impact on Revenue: The company faced a cyber incident that negatively impacted Q4 revenue by approximately $4.5 million, which reduced revenue growth by an estimated 5%.
Tissue Processing Revenue Decline: Tissue processing revenues declined by 8% year-over-year in Q4, indicating challenges in this segment due to the cyber incident.
Revenue Growth with Supply Challenges: Despite overall revenue growth of 3% in Q4, the company experienced a slowdown in tissue and On-X supply, which is expected to affect Q1 2025 revenues significantly.
Tissue Revenue Decline: The company anticipates that tissue revenues will be significantly lower-than-normal in Q1 2025, with a backlog expected to be cleared later in the year.
Rising Operational Costs: General, administrative, and marketing expenses increased slightly from $50.3 million in Q4 2023 to $51.4 million in Q4 2024, indicating rising operational costs.
Rising Interest Expenses: Interest expenses rose sharply to $9.4 million in Q4 2024 from $5.8 million in the prior year, reflecting increased financial burdens.
Cyber Expense Impact: The company expects to incur additional cyber-related expenses in 2025, which could further strain financial performance.
Artivion, Inc. (NYSE:AORT) Q4 2024 Earnings Call Transcript
AORT.N
2.99%